Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Stock Short Interest Climbs 60.0%

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 9,061 shares, an increase of 60.0% from the August 31st total of 5,662 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 18,160 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Trading of Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Susquehanna International Group LLP boosted its position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 14,064 shares of the company’s stock after acquiring an additional 4,046 shares during the period. Susquehanna International Group LLP owned about 0.17% of Cryo-Cell International worth $45,000 at the end of the most recent reporting period. 10.44% of the stock is owned by hedge funds and other institutional investors.

Cryo-Cell International Price Performance

Shares of NYSEAMERICAN CCEL traded up $0.15 on Wednesday, hitting $4.20. The company’s stock had a trading volume of 2,160 shares, compared to its average volume of 12,989. Cryo-Cell International has a 12-month low of $2.72 and a 12-month high of $4.90. The company has a market capitalization of $33.85 million, a price-to-earnings ratio of -14.00 and a beta of 0.47. The stock has a 50 day moving average of $3.97 and a 200-day moving average of $3.66.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $0.07 EPS for the quarter. The company had revenue of $7.78 million for the quarter.

About Cryo-Cell International

Cryo-Cell International, Inc is a biotechnology and healthcare services company focused on the collection, processing, testing and long-term storage of umbilical cord blood and cord tissue. The company provides families with access to private stem cell banking services intended to preserve potentially valuable biological material for future medical use.

Its services generally include coordinating the collection of cord blood and tissue at birth, transporting specimens to its processing facilities, isolating and cryopreserving stem cells, and maintaining the stored materials under controlled conditions.